On November 15, 2018 Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women’s health and endocrine diseases, reported its participation in the following upcoming investor conferences (Press release, Myovant Sciences, NOV 15, 2018, http://investors.myovant.com/news-releases/2018/11-15-2018-132944791 [SID1234531386]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI HealthConX Conference in Boston, MA. President and Chief Executive Officer, Lynn Seely, M.D., will participate in a fireside chat on Tuesday, November 27, 2018, at 9:30 a.m. ET.
Citi’s 2018 Global Healthcare Conference in New York, NY. Myovant will host meetings with investors on Wednesday, December 5 and Thursday, December 6, 2018.

A live webcast of the Evercore presentation will be accessible on the Events page under the Investors and Media section of the Myovant website at www.myovant.com. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay of the webcast will be available for 30 days following the conference.